New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
09:15 EDTADMP, IGT, BDSI, ISRG, SBUX, GWW, PTCT, XRX, KMB, MSFT, FEYE, ENDP, SWK, JNPR, KSUOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Microsoft (MSFT), up 3.5%... Starbucks (SBUX), up 1.2%... Juniper (JNPR), up 5.4%... Kimberly Clark (KMB), up 2%... Stanley Black & Decker (SWK), up 1%. ALSO HIGHER: BioDelivery (BDSI), up 43% after announcing positive top-line results from BEMA Phase III trial with Endo (ENDP) unit... Adamis (ADMP), up 6% after receiving Notice of Allowance of patent claims for immunotherapy portfolio. DOWN AFTER EARNINGS: International Game (IGT), down 11%... Intuitive Surgical (ISRG), down 5.5%... Xerox (XRX), down 2.6%... W.W. Grainger (GWW). down 4.5%... Kansas City Southern (KSU), down 8%. ALSO LOWER: PTC Therapeutics (PTCT), down 18% after announcing EMA adopted negative opinion on MAA for Atuluren approval... FireEye (FEYE), down 2.4% following downgrade at Barclays.
News For MSFT;SBUX;JNPR;KMB;ISRG;SWK;XRX;BDSI;ENDP;PTCT;IGT;FEYE;GWW;KSU;ADMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
July 16, 2015
11:36 EDTBDSIBioDelivery Sciences management to meet with FBR Capital
Meetings to be held in Minneapolis on July 22 and in Dallas on July 23 hosted by FBR Capital.
10:00 EDTSBUXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTKSUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTMSFTMicrosoft to acquire FieldOne Systems, terms not disclosed
Subscribe for More Information
09:01 EDTSBUXStarbucks to open stores in 15 low to medium income communities across U.S.
Subscribe for More Information
08:36 EDTFEYEFinjan Holdings files second lawsuit against Blue Coat
Finjan Holdings (FNJN) announced that its subsidiary, Finjan, Inc. has filed a second patent infringement lawsuit against Blue Coat Systems, alleging infringement of seven Finjan patents relating to new infringing Blue Coat products and services. The Complaint, filed July 15, 2015, in the U.S. District Court for the Northern District of California, alleges that Blue Coat's new products and services infringe seven Finjan patents. In particular, Finjan is asserting infringement of U.S. Patent Nos. 6,154,844; 6,965,968; 7,418,731; 8,079,086; 8,225,408; 8,566,580; 8,677,494; four of which are being asserted against Blue Coat for the first time. Finjan is seeking a jury trial; entry of judgment of direct and indirect infringement of certain claims of each of the asserted patents by Blue Coat; preliminary and permanent injunction against Blue Coat and its officers, among others, from infringing the asserted patents; and damages to be determined by a jury. This original case against Blue Coat will be proceeding to trial on July 20, 2015, with all six patents included in Finjan's first complaint against Blue Coat. Those patents include 6,804,780; 6,154,844; 7,418,731; 6,965,968; 7,058,822 and 7,647,633. The trial in the first case is expected to last for two weeks. Finjan has filed patent infringement lawsuits against FireEye (FEYE), Proofpoint, Sophos, Symantec (SYMC), and Palo Alto Networks (PANW) relating to, collectively, more than 20 patents in the Finjan portfolio.
08:06 EDTIGTInternational Game subsidiary to be awarded 7-year contract by Wisconsin Lottery
Subscribe for More Information
06:52 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
05:46 EDTMSFTMicrosoft may increase smartphone outsourcing in Taiwan, Vietnam, DigiTimes says
Subscribe for More Information
05:46 EDTMSFTMicrosoft's new Surface expected to be available in October, DigiTimes reports
Microsoft's new Surface tablet is expected to be launched in October after upstream supply chains have been notified to start mass shipments of components in September, reports DigiTimes. According to sources, Microsoft's Surface Pro shipments were 200K-250K units per month in Q1 and its monthly tablet shipment volume rose to above 300K. Sources say Microsoft's monthly tablet shipments may have a chance to reach 500K-600K units. Reference Link
05:41 EDTKSUKansas City Southern downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Brandon Oglenski downgraded Kansas City Southern to Underweight and other rail names after lowering his rating on the North America Airfreight & Ground Transportation space to Neutral from Positive. The analyst sees a lack of positive catalysts amid softer industrial demand, high relative inventories and U.S. dollar appreciation. He lowered his price target for shares to $93 from $112.
July 15, 2015
16:28 EDTPTCTOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
16:22 EDTSBUXStarbucks initiated with a Buy at BTIG
Target $64.
13:11 EDTMSFTWindows 10 finalized, the Verge reports
Microsoft has finalized its Windows 10 software, ready for release on July 29, the Verge reports. The company is signing off on the build, known as build 10240, internally and may announce the manufacturing copy publicly by the end of the week, the report says. Reference Link
12:18 EDTPTCTOn The Fly: Top stock stories at midday
Subscribe for More Information
10:01 EDTKSUKansas City Southern names Brian Hancock as EVP, CMO
Subscribe for More Information
08:19 EDTKSUCSX quarter likely to be 'least bad' one in rail space, says Stephens
Subscribe for More Information
08:03 EDTJNPRJuniper names Bob Worrall as SVP, Chief Information Officer
Subscribe for More Information
06:45 EDTPTCTJPMorgan upgrades PTC Therapeutics with $100 target ahead of data
JPMorgan analyst Anupam Rama upgraded PTC Therapeutics (PTCT) to Overweight from Neutral citing an attractive risk/reward profile into the phase 3 results for Translarna in non-sense mutation Duchenne Muscular Dystrophy. The data are expected in Q4. Rama believes the study is designed for success and raised the firm's probability of success to 80%. PTC shares are off down 37% since the mid-March highs when takeout speculation was a key driver of appreciation, Rama tells investors this morning in a research note. The analyst raised PTC's price target to $100 from $74. Shares of PTC closed yesterday up $1.30 to $48.94.
06:44 EDTPTCTPTC Therapeutics upgraded to Overweight from Neutral at JPMorgan
Price target raised to $100 from $74.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use